JP2025507569A5 - - Google Patents

Info

Publication number
JP2025507569A5
JP2025507569A5 JP2024548410A JP2024548410A JP2025507569A5 JP 2025507569 A5 JP2025507569 A5 JP 2025507569A5 JP 2024548410 A JP2024548410 A JP 2024548410A JP 2024548410 A JP2024548410 A JP 2024548410A JP 2025507569 A5 JP2025507569 A5 JP 2025507569A5
Authority
JP
Japan
Prior art keywords
seq
chain variable
variable region
sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548410A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507569A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/053940 external-priority patent/WO2023156549A1/en
Publication of JP2025507569A publication Critical patent/JP2025507569A/ja
Publication of JP2025507569A5 publication Critical patent/JP2025507569A5/ja
Pending legal-status Critical Current

Links

JP2024548410A 2022-02-16 2023-02-16 ヒト化抗tdp-43結合分子およびその使用 Pending JP2025507569A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP22157150.8 2022-02-16
EP22157150 2022-02-16
EP22177361 2022-06-06
EP22177361.7 2022-06-06
EP23152958.7 2023-01-23
EP23152958 2023-01-23
EP23153165.8 2023-01-24
EP23153165 2023-01-24
PCT/EP2023/053940 WO2023156549A1 (en) 2022-02-16 2023-02-16 Humanized anti-tdp-43 binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2025507569A JP2025507569A (ja) 2025-03-21
JP2025507569A5 true JP2025507569A5 (https=) 2026-02-24

Family

ID=85239102

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548410A Pending JP2025507569A (ja) 2022-02-16 2023-02-16 ヒト化抗tdp-43結合分子およびその使用

Country Status (13)

Country Link
US (1) US20250145695A1 (https=)
EP (1) EP4479426A1 (https=)
JP (1) JP2025507569A (https=)
KR (1) KR20240150774A (https=)
AR (1) AR128540A1 (https=)
AU (1) AU2023221539A1 (https=)
CA (1) CA3243689A1 (https=)
CL (1) CL2024002383A1 (https=)
CR (1) CR20240378A (https=)
IL (1) IL315043A (https=)
MX (1) MX2024009948A (https=)
TW (1) TW202342519A (https=)
WO (1) WO2023156549A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11252156B2 (en) * 2012-05-31 2022-02-15 Ikonopedia, Inc. Secure data transmission
AU2024341632A1 (en) * 2023-09-15 2026-04-23 Prothena Biosciences Limited Compositions and methods of reducing immunogenicity and improving stability of antibodies
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof
WO2025186332A1 (en) 2024-03-05 2025-09-12 Ac Immune Sa Vectorized anti-tdp-43 antibodies
KR20260044274A (ko) * 2024-09-23 2026-04-02 주식회사 피플바이오 Tdp-43에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
ATE191853T1 (de) 1992-07-27 2000-05-15 Us Health Zielgerichte liposome zur blut-hirne schranke
FR2707189B1 (fr) 1993-07-09 1995-10-13 Gradient Ass Procédé de traitement de résidus de combustion et installation de mise en Óoeuvre dudit procédé.
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
PL209392B1 (pl) 1999-01-15 2011-08-31 Genentech Inc Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20020065259A1 (en) 2000-08-30 2002-05-30 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP2141243A3 (en) 2000-10-16 2010-01-27 Brystol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
CA2481925A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for patients having human fc.gamma.riiia
EP1500400A4 (en) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk MEDICAMENT WITH ANTIBODY COMPOSITION
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2007505142A (ja) 2003-09-10 2007-03-08 セダーズ−シナイ メディカル センター 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008151055A1 (en) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnosing neurodegenerative diseases
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US9587014B2 (en) 2011-10-28 2017-03-07 Biogen International Neuroscience Gmbh TDP-43 specific binding molecules
JP6325463B2 (ja) 2012-03-16 2018-05-16 コヴァジェン アクチェン ゲゼルシャフト 抗腫瘍活性を有する新規結合分子
AU2020278907A1 (en) 2019-05-23 2022-01-20 Ac Immune Sa Anti-TDP-43 binding molecules and uses thereof
TW202221026A (zh) 2020-08-14 2022-06-01 瑞士商Ac 免疫有限公司 人源化抗tdp-43結合分子及其用途

Similar Documents

Publication Publication Date Title
JP2025507569A5 (https=)
JP2023537761A5 (https=)
EP1838348B1 (en) Humanized amyloid beta antibodies for use in improving cognition
JP7307446B2 (ja) RGMa結合タンパク質及びその使用
KR101455479B1 (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
JP2022533432A5 (https=)
TW201902924A (zh) 抗-N3pGlu類澱粉β肽抗體及其用途
CN108431044A (zh) 抗age抗体及其使用方法
JP7760626B2 (ja) 治療に使用するための抗ソルチリン抗体
TW201206479A (en) Immunotherapy regimes dependent on ApoE status
US20180312577A1 (en) Anti-age antibodies and methods of use thereof
CN105431203A (zh) 治疗性融合蛋白
TW201636371A (zh) 抗甲狀腺素運送蛋白抗體
CN110997715A (zh) 用于治疗突触核蛋白病的组合物和方法
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
TW202142569A (zh) 抗cd98抗體及其用途
JP2023528535A (ja) セリン413においてリン酸化されたタウを標的化する高親和性抗体
JP2025535203A (ja) タウ結合化合物
TWI734279B (zh) 抗α-突觸核蛋白抗體及其用途
Schellhammer et al. Exit pathways of therapeutic antibodies from the brain and retention strategies
JP2025513799A5 (https=)
US20210347869A1 (en) Methods and compositions for treating tauopathies
KR20230093499A (ko) 인간 대상체에서 타우를 감소시키는 방법
EP4023677A9 (en) Monoclonal antibody which targets tfpi
US20200385461A1 (en) Fusion constructs and uses thereof